1. |
New therapeutic approaches for uterine fibroids |
|
Inpharma Weekly,
Volume &NA;,
Issue 1273,
2001,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
2. |
News in brief... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1273,
2001,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
3. |
Lovastatin worth its cost |
|
Inpharma Weekly,
Volume &NA;,
Issue 1273,
2001,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
4. |
Levonorgestrel-releasing device better value than hysterectomy |
|
Inpharma Weekly,
Volume &NA;,
Issue 1273,
2001,
Page 5-5
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
5. |
News in brief... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1273,
2001,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
6. |
STI 571 strengthens its standing in CML |
|
Inpharma Weekly,
Volume &NA;,
Issue 1273,
2001,
Page 7-8
Sushma Soni,
Preview
|
|
摘要:
The concept of molecular targeting as a tool in the development of cancer therapies is gaining increasing prominence, and the tyrosine kinase inhibitor STI 571 ['Glivec'] seems to have become a poster child for the concept. The results seen with STI 571 in clinical studies have borne out the viability of the molecular targeting approach. Positive data from numerous studies involving the agent were presented at the 42nd Annual Meeting of the American Society of Hematology*(ASH) [San Francisco, US; December 2000]. In particular, researchers were proclaiming the potential importance of STI 571 for the treatment of chronic myeloid leukaemia (CML), following on from the promising results presented at the 1999 ASH meeting.**
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
7. |
News in brief... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1273,
2001,
Page 9-9
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
8. |
Retigabine: on its way to proving its worth in epilepsy |
|
Inpharma Weekly,
Volume &NA;,
Issue 1273,
2001,
Page 10-11
Jo Dalton,
Preview
|
|
摘要:
Wyeth-Ayerst and Asta Medica are collaborating on the development of retigabine, the first potassium channel opener anticonvulsant that acts on an ion channel directly linked to epilepsy. The combination of this unique activity with potentiation of γ-aminobutyric acid (GABA), an established anticonvulsant mechanism of action, makes retigabine particularly interesting. It is hoped that such a novel drug will one day be the key to treating patients with drug-resistant epilepsy. At the 54th Annual Meeting of the American Epilepsy Society [Los Angeles, US; December 2000] Wyeth-Ayerst and Asta Medica presented early clinical data that have been collected in the lead-up to phase II clinical testing of retigabine. Results of a currently ongoing phase IIb multinational, placebo-controlled trial will be instrumental in indicating whether retigabine will fulfil its early potential and go on to become the first 'third generation' anticonvulsant to reach the market.
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
9. |
Formoterol prolongs time to first severe asthma exacerbation |
|
Inpharma Weekly,
Volume &NA;,
Issue 1273,
2001,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|
10. |
News in brief... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1273,
2001,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2001
数据来源: ADIS
|